Role of bridging therapy during chimeric antigen receptor T cell therapy

eJHaem

article

Shakthi T. Bhaskar¹  Bhagirathbhai R. Dholaria¹  Salyka M. Sengsayadeth¹  Bipin N. Savani¹  Olalekan O. Oluwole¹ 

[1] Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center

关键词: bridging therapy;    chimeric antigen receptor T cell therapy;    hematologic malignancies;   

DOI  :  10.1002/jha2.335

来源: Wiley

【 摘 要 】

Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent outcomes to those in clinical trials. However, increased real-world use of CAR T therapy has uncovered a number of barriers that can lead to significant delays in treatment. As a result, bridging therapy has become a widely used tool to stabilize or debulk disease between leukapheresis and CAR T cell administration. Here we review the available data regarding bridging therapy, with a focus on patient selection, choice of therapy, timing of therapy, and potential pitfalls.

【 授权许可】

Unknown